Details of the Drug
General Information of Drug (ID: DM16P3N)
Drug Name |
4-chloro-7-methyl-1H-indole-2,3-dione
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
61258-72-8; 4-Chloro-7-methyl isatin; 4-Chloro-7-methyl-1H-indole-2,3-dione; 4-chloro-7-methylisatin; 4-chloro-7-methylindoline-2,3-dione; 4-chloro-7-methyl-2,3-dihydro-1H-indole-2,3-dione; 1H-Indole-2,3-dione,4-chloro-7-methyl-; 1H-Indole-2,3-dione, 4-chloro-7-methyl-; AC1LXYLJ; AC1Q2GPB; Isatin-based compound, 55; Cambridge id 5226020; MLS002473344; SCHEMBL950949; CHEMBL373715; CTK5B2947; BDBM22835; DTXSID20365244; MolPort-002-111-842; MWCJCUFHPFXQLS-UHFFFAOYSA-N; HMS2228G20; ZINC2169011; ALBB-024400; SBB066723; BBL005527
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 195.6 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.7 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||